



9<sup>th</sup> August 2012

Dear Healthcare Provider,

**Availability of Mabcampath (alemtuzumab)**

This letter is intended to inform you that Genzyme, a Sanofi company, and its affiliates (hereinafter collectively referred to as the Company) has surrendered the licence for all presentations of alemtuzumab effective as of August 8<sup>th</sup> 2012. This means that alemtuzumab will no longer be available as a licensed product in the UK once existing supplies run out.

This action is not being taken for any reasons related to product safety, efficacy or supply, but as part of the Company's plan for bringing alemtuzumab forward as a treatment for a new indication.

In agreement with the MHRA, the Company will continue to supply alemtuzumab commercially until existing stocks run out; following that alemtuzumab will be available through a patient access programme for oncological and transplant indications. The Company will continue manufacturing sufficient quantities of alemtuzumab to supply this patient access program.

Until existing stocks run out you can continue to order MabCampath through customer services at Genzyme on +44 (0) 1865 405235 or by email [customer.services@genzyme.com](mailto:customer.services@genzyme.com).

For further information on the patient access programme please contact Clinigen's Customer Service team via phone on +44 (0) 1283 494 340, or via fax on +44 (0) 1283 494 341 or by email [customer.service@clinigen.co.uk](mailto:customer.service@clinigen.co.uk).

If you have any questions or concerns, please contact the medical information department on telephone number 0800 281 973 or by email on [uk-medicalinformation@sanofi.com](mailto:uk-medicalinformation@sanofi.com).

We apologise for any difficulties and misunderstandings over supply of MabCampath.

Yours Sincerely,

A handwritten signature in black ink that reads "Jasmin Hussein".

Dr Jasmin Hussein MB.BChir FRCS  
Medical Manager Oncology UK